Biobeat Technologies Names Raymond W. Cohen as Chairman of the Board of Directors

TEL AVIV, Israel & MIAMI--(BUSINESS WIRE)-- Biobeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, today announced the appointment of Raymond W. Cohen as its Chairman of the Board of Directors.

Biobeat developed and has received FDA clearance for an easy-to-apply “patch” device that can collect, record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters, including continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output.

“We welcome Raymond W. Cohen as our new Chairman,” said Arik Ben Ishay, co-founder and CEO of Biobeat. “Ray’s extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology.”

Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of life science industry experience. He was the co-founder and CEO of publicly traded Axonics, Inc., a global leader in implantable neuromodulation devices that completed its initial public offering in late 2018. Under his leadership, Axonics generated over $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America, and was acquired by Boston Scientific in November 2024 for $3.7 billion. In March 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical stage renal denervation company, led the sale of SoniVie to Boston Scientific for $600 million.

“Biobeat has accomplished what has been an elusive goal for many – a clinically validated and FDA cleared cuff-less ABPM that has the potential to change the use paradigm for measuring ambulatory blood pressure. We see numerous applications for this technology in the new field of renal denervation (RDN) as well as long term monitoring of post-cardiac procedure and CHF patients following discharge from the hospital,” said Mr. Cohen. “I look forward to collaborating with the management team to support the company’s mission to change the way patients are monitored.”

Cohen currently serves on the boards of several public and venture capital backed innovative healthcare companies, including Kestra Medical Technologies (Nasdaq: KMTS); InspireMD (Nasdaq: NSPR); RxSight (Nasdaq: RXST), privately held Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. Mr. Cohen also serves as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners.

About Biobeat Technologies, Ltd

Biobeat based in Israel with offices in Boca Raton Florida, is a privately held company that has developed wearable, non-invasive cuffless ambulatory blood pressure monitoring technology that enables continuous, blood pressure measurements, respiratory rate, Sp02, ECG, pulse rate, body temperature, stroke volume, cardiac output, systemic vascular resistance and other key physiological parameters. By comparison, unlike traditional ABPM system, Biobeat offers a cuff-less small unobtrusive “patch” device with enhanced patient comfort, especially during sleep while collecting and transmitting real time data to a mobile app. Biobeat’s products are 510(k) cleared by the US Food & Drug Administration.

For more information: www.bio-beat.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250821891096/en/

Media Contact:

Sharon Dayan

VP Marketing

Sharon.dayan@bio-beat.com

Source: BioBeat Technologies Ltd